Important limitations include: Most evidence derives from preclinical or observational studies No randomized controlled trials specifically evaluate tirzepatide for autoimmune disease Mechanisms remain incompletely understood Clinical translation of anti-inflammatory effects is uncertain There is currently no established clinical evidence that tirzepatide effectively treats autoimmune diseases
If you are comparing the two for weight loss, it is not close
Lower Inflammation Levels Reduced systemic inflammation creates a healthier internal environment, less conducive to cancer
Allelic loss of the gene for the GPX1 selenium-containing protein is a common event in cancer
The most widely used consensus, that of the ADA/EASD, ranks SUs as the last option for patients with established cardiovascular or renal disease, and suggests that they should only be prioritized when cost is an issue [10]
According to the International Diabetes Federation (IDF) in 2021, approximately 537 million adults aged 2079 worldwide have diabetes, which is expected to rise to 783 million by 2045 (Ogurtsova et al., 2022)
